Morgan Stanley raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $35 from $32 and keeps an Overweight rating on the shares. Q4 sales came in ahead of expectations and management raised full-year net product revenue guidance set previously with Q3, the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Therapeutics: Commercial Outperformance and Upgraded Zoryve Outlook Support Buy Rating
- Arcutis Biotherapeutics: Zoryve’s Outperformance and Strengthening Outlook Support Buy Rating and Higher $36 Target
- Arcutis Biotherapeutics price target raised to $34 from $30 at H.C. Wainwright
- Arcutis: Strong Zoryve Outperformance, Upgraded 2026 Outlook, and Pipeline Momentum Support Buy Rating
- Arcutis Biotherapeutics files automatic mixed securities shelf